Browse by products

Featured content

  • Abinscience provides high-quality tools for studying viruses, superbugs, and parasites, including monkeypox, Ebola, and other emerging pathogens, supporting diagnostics, vaccine development, and therapeutic discovery.
  • Abinscience provides tools for studying Alzheimer's, Parkinson's, and Huntington's disease, supporting biomarkers, diagnostics, and therapy development in neuroscience.
  • Abinscience provides tools for studying therapeutic targets, including CD3E, CTLA4, PD1, PDL1, B7-H3, CEA, CD200R1, SIRPA, and CCR8, supporting biomarkers, diagnostics, and therapy development.
  • Abinscience offers anti-dsRNA antibodies (J2, K1, K2), widely recognized in virology, immunology, and RNA research for their exceptional specificity and sensitivity, empowering scientists to explore the RNA world
  • Reliable antibodies for botulinum, ricin, tetanus, and other toxins, enabling sensitive detection and toxin research.
  • High-specificity antibodies and ELISA kits for key targets like TNF-α, IL-6, IFN-γ, PD-1, and CTLA-4, enabling reliable cytokine detection and immune regulation studies.
  • Specific antibodies for MHC I, MHC II, and related molecules, supporting antigen presentation, immune response, and disease research.
  • Targeting tumor-associated carbohydrate antigens (Tn, STn, MUC1, CA15-3, CA72-4) to support cancer immunotherapy and biomarker research
  • About Abinscience

    News

  • Discover high-quality Norovirus research solutions, including recombinant proteins, antibodies. Learn about Norovirus structure, vaccine development, and diagnostics to advance your virology research.
  • Influenza and RSV cause seasonal outbreaks, posing risks to infants and the elderly. Key proteins like Hemagglutinin (HA), Neuraminidase (NA), and RSV Fusion Glycoprotein (F) are vital for vaccine and antiviral research. Abinscience offers recombinant proteins, antibodies, and ELISA kits to advance virology studies in diagnostics and therapeutics.
  • Bispecific antibodies (BsAbs) are revolutionizing cancer and immunotherapy, with Merck & Co. investing $1.3 billion in CD19/CD3 BsAb CN201. Learn how BsAbs enhance immune activation and tumor elimination.
  • Explore the structure, function, and clinical significance of CD77, a key glycosphingolipid involved in Burkitt lymphoma, Shiga toxin interaction, and targeted cancer therapy. Learn about its applications in flow cytometry and biomedical research with high-quality CD77 antibodies and reagents.